As of 2025-11-03, the Intrinsic Value of Atea Pharmaceuticals Inc (AVIR) is -42.88 USD. This Atea valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.25 USD, the upside of Atea Pharmaceuticals Inc is -1,419.47%.
Based on its market price of 3.25 USD and our intrinsic valuation, Atea Pharmaceuticals Inc (AVIR) is overvalued by 1,419.47%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -42.88 - -42.88 | -42.88 | -1,419.47% |
| P/E | (32.97) - (35.75) | (34.56) | -1163.5% |
| DDM - Stable | (10.83) - (39.14) | (24.98) | -868.7% |
| DDM - Multi | (11.61) - (34.40) | (17.57) | -640.6% |
| Market Cap (mil) | 257.92 |
| Beta | 0.42 |
| Outstanding shares (mil) | 79.36 |
| Enterprise Value (mil) | 170.20 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.52% |
| Cost of Debt | 5.00% |
| WACC | 8.23% |